ACP-196 (Acalabrutinib) in Combination with Pembrolizumab, for Treatment of Hematologic Malignancies - KEYNOTE145

Study identifier:ACE-LY-005

ClinicalTrials.gov identifier:NCT02362035

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

A Phase 1b/2 Proof-of-Concept Study of the Combination of ACP-196 (Acalabrutinib) and Pembrolizumab in Subjects with Hematologic Malignancies

Medical condition

Follicular lymphoma (FL)

Phase

Phase 1/2

Healthy volunteers

No

Study drug

Acalabrutinib, Pembrolizumab

Sex

All

Actual Enrollment

161

Study type

Interventional

Age

18 Years - n/a

Date

Study Start Date: 20 Feb 2015
Primary Completion Date: 14 Jul 2020
Estimated Study Completion Date: 01 Apr 2026

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Jul 2024 by AcertaPharma

Sponsors

AcertaPharma

Collaborators

Merck

Inclusion and exclusion criteria